Assessing immune profiles to predict responses to cancer immunotherapy
Immune Profiling for Cancer Immunotherapy Response
Dartmouth-Hitchcock Medical Center · NCT06116032
This study is testing if certain immune profiles can help predict how well cancer patients will respond to approved immunotherapy treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Dartmouth-Hitchcock Medical Center (other) |
| Drugs / interventions | pembrolizumab, nivolumab, ipilimumab, immunotherapy |
| Locations | 1 site (Lebanon, New Hampshire) |
| Trial ID | NCT06116032 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the predictive value of immune-methylation profiling in patients undergoing FDA-approved immunotherapy for various types of cancer. It will analyze both pre-treatment and on-treatment immune-methylation and cytokine profiles to determine their effectiveness in predicting treatment responses. The study focuses on patients receiving therapies such as checkpoint inhibitors and cellular immunotherapy, regardless of their prior treatment history.
Who should consider this trial
Good fit: Ideal candidates for this study are cancer patients who are currently receiving or are scheduled to receive FDA-approved immunotherapy.
Not a fit: Patients who are pregnant, prisoners, or decision-impaired will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict which cancer patients will respond best to immunotherapy, leading to more personalized treatment plans.
How similar studies have performed: Other studies have shown promise in using immune profiling to predict responses to immunotherapy, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy). * Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included). Exclusion Criteria: * Pregnant women/fetuses/neonates * Prisoners * Decision-impaired individuals
Where this trial is running
Lebanon, New Hampshire
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States (RECRUITING)
Study contacts
- Principal investigator: Brock C Christensen, PhD — Dartmouth College
- Study coordinator: Brock C Christensen, PhD
- Email: brock.c.christensen@dartmouth.edu
- Phone: 603-650-1827
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer, Tumor, Solid, Hematologic Malignancy, Blood Cancer, Immunotherapy